[35] Mann VH, Huang T,

Cheng Q, Saul A. Sequence variation in the circumsporozoite protein gene of *Plasmodium vivax* appears to be regionally biased. Molecular and Biochemical Parasitology. 1994;**68**(1):45-52

[36] Sattabongkot J, Suwanabun N, Rongnoparut P, Wirtz RA, Kain KC, Rosenberg R. Comparative test of DNA probes for detection of *plasmodium vivax* circumsporozoite protein polymorphs VK247 and VK210. The Journal of Infectious Diseases. 1994;**169**(2):464- 466. DOI: 10.1093/infdis/169.2.464. PMID: 8106786

[37] Dias S, Wickramarachchi T, Sahabandu I, Escalante AA, Udagama PV. Population genetic structure of the *plasmodium vivax* circumsporozoite protein (Pvcsp) in Sri Lanka. Gene. 2013;**518**:381-387

[38] Moon SU, Lee HW, Kim JY, Na BK, Cho SH, Lin K, et al. High frequency of genetic diversity of *plasmodium vivax* field isolates in Myanmar. Acta Tropica. 2009;**109**:30-36

[39] Shabani SH, Zakeri S, Mehrizi AA, Mortazavi Y, Djadid ND. Population genetics structure of *plasmodium vivax* circumsporozoite protein during the elimination process in low and unstable malaria transmission areas, southeast of Iran. Acta Tropica. 2016;**160**:23-34

[40] Chan CW, Sakihama N, Tachibana S-II, Idris ZM, Lum JK, Tanabe K, et al. *Plasmodium vivax* and *plasmodium falciparum* at the crossroads of exchange among islands in Vanuatu: Implications for malaria elimination strategies. PLoS One. 2015;**10**:e0119475

[41] Ling Zhang L, Nong Yao L, Liang Chen H, Yi Lu Q, Ruan W. Genetic diversity analysis of PvCSP and its application in tracking of *plasmodium vivax*. Experimental Parasitology. 2018;**188**:26-35

[42] Parobek CM, Bailey JA, Hathaway NJ, Socheat D, Rogers WO, Juliano JJ. Differing patterns of selection and geospatial genetic diversity within two leading *plasmodium vivax* candidate vaccine antigens. PLoS Neglected Tropical Diseases. 2014;**8**:e2796

[43] Zakeri S, Raeisi A, Afsharpad M, Kakar Q, Ghasemi F, Atta H, et al. Molecular characterization of *plasmodium vivax* clinical isolates in Pakistan and Iran using pvmsp-1, pvmsp-3α and pvcsp genes as molecular markers. Parasitology International. 2010;**59**:15-21

[44] Storti-Melo LM, de Souza-Neiras WC, Cassiano GC, Joazeiro AC, Fontes CJ, Bonini-Domingos CR, et al. *Plasmodium vivax* circumsporozoite variants and

Duffy blood group genotypes in the Brazilian Amazon region. Transactions of the Royal Society of Tropical Medicine and Hygiene. 2009;**103**:672-678

[45] Võ TC, Lê HG, Kang JM, Moe M, Naw H, Myint MK, et al. Genetic polymorphism and natural selection of circumsporozoite protein in Myanmar *plasmodium vivax*. Malaria Journal. 2020;**19**(1):303

[46] Simon B, Sow F, Al Mukhaini SK, Al-Abri S, Ali OAM, Bonnot G, et al. An outbreak of locally acquired *plasmodium vivax* malaria among migrant workers in Oman. Parasite. 2017;**24**:25

[47] Liu Y, Zhou RM, Zhang YL, Wang DQ, Li SH, Yang CY, et al. Analysis of polymorphisms in the circumsporozoite protein gene of *plasmodium vivax* isolates from Henan Province. China. Malar J. 2018;**17**(1):103

[48] WHO. World Health Organization. World Malaria Report. World 2019. World Health Organization. Geneva, Switzerland 2019. Available at: https:// www.mmv.org/sites/default/files/ uploads/docs/publications/World%20 Malaria%20Report\_0.pdf. Accessed on: 5-04-2020

[49] Gonzalez-Cerón L, Rodriguez MH, Nettel JC, Villarreal C, Kain KC, Hernandez JE. Differential susceptibilities of *Anopheles albimanus* and *Anopheles pseudopunctipennis* to infections with coindigenous *plasmodium vivax* variants VK210 and VK247 in southern Mexico. Infection and Immunity. 1999;**67**:410-412

[50] Gonzalez-Cerón L, Alvarado-Delgado A, Martinez-Barnetche J, Rodriguez MH, Ovilla-Munoz M, Perez F, et al. Sequence variation of ookinete surface proteins Pvs25 and Pvs28 of *plasmodium vivax* isolates from *Circumsporozoite Protein from* Plasmodium vivax *and Its Relationship to Human Malaria DOI: http://dx.doi.org/10.5772/intechopen.102529*

southern Mexico and their association to local anophelines infectivity. Infection, Genetics and Evolution. 2010;**10**:645-654

[51] Hernandez-Martinez MA, Escalante AA, Arevalo-Herrera M, Herrera S. Antigenic diversity of the *plasmodium viva*x circumsporozoite protein in parasite isolates of Western Colombia. The American Journal of Tropical Medicine and Hygiene. 2011;**84**:51-57

[52] Naranjo-Díaz N, Altamiranda M, Luckhart S, Conn JE, Correa MM. Malaria vectors in ecologically heterogeneous localities of the Colombian Pacific region. PLoS One. 2014;**9**(8):e103769

[53] Mendizábal-Cabrera R, Padilla N. Diversidad genética de Plasmodium Vivax Em Regiones de Alto Riesgo de Malaria en Guatemala [Genetic Diversity of. *Plasmodium Vivax* in Areas of High Risk of Malaria in Guatemala]. Guatemala: Revista de la Universidad del Valle de Guatemala; 2006. pp. 62-79

[54] Lopez AC, Ortiz A, Coello J, Sosa-Ochoa W, Torres RE, Banegas EI, et al. Genetic diversity of *plasmodium vivax* and *plasmodium falciparum* in Honduras. Malaria Journal. 2012;**11**:391

[55] Machado RL, Póvoa MM. Distribution of *plasmodium vivax* variants (VK210, VK247 and *P. vivax*like) in three endemic areas of the Amazon region of Brazil and their correlation with chloroquine treatment. Transactions of the Royal Society of Tropical Medicine and Hygiene. 2000;**94**:377-381

[56] Machado RL, de Filho AF, Calvosa VSP, Figueredo MC, Nascimento JM, Póvoa MM. Correlation between *plasmodium vivax* variants in Belém, Pará state, Brazil and symptoms

and clearance of parasitaemia. Brazilian J Infect Dis. 2003;**7**:175-177

[57] Santos EA, Primo DG, Sucupira IMC, Cassiano GC, Barbosa DRL, Vianna GMR, et al. Frequency of *Plasmodium vivax* circumsporozoite protein genotypes in humans and anopheline mosquitoes in an endemic area of southeastern Pará state, Brazil. Revista Pan-Amazônica de Saúde. 2016;**7**:57-64

[58] Gomes MD, Vieira JL, Cassiano GC, Musset L, Legrand E, Nacher M, et al. Evaluation of Cimcrusporozoite Protein of *Plasmodium vivax* to estimate its prevalence in Oiapoque, Amapá State, Brazil, Bordering French Guiana. Revista do Instituto de Medicina Tropical de São Paulo. 2016;**58**:72

[59] de Ribeiro BP, Cassiano GC, de Souza RM, Cysne DN, Grisotto MA, de Azevedo dos Santos AP, et al. Polymorphisms in *Plasmodium vivax* Circumsporozoite protein (CSP) influence parasite burden and cytokine balance in a pre-Amazon endemic area from Brazil. PLoS Neglected Tropical Diseases. 2016;**10**(3):e0004479

[60] Almeida-de-Oliveira NK, Abreu-Fernandes R, Lima-Cury L, Lavigne AR, Pina-Costa A, Perceda-Silva DS, et al. Balancing selection and high genetic diversity of *plasmodium vivax* circumsporozoite central region in parasites from Brazilian Amazon and Rio de Janeiro Atlantic Forest. PLoS One. 2020;**15**(11):e0241426

[61] Silva AN, Santos CC, Lacerda RN, Machado RL, Póvoa MM. Susceptibility of *Anopheles aquasalis* and *An. darlingi* to *Plasmodium vivax* VK210 and VK247. Memórias do Instituto Oswaldo Cruz. 2006;**101**:547-550

[62] Branquinho MS, Araújo MS, Natal D, Marrelli MT, Rocha RM, Taveira FA, et al. *Anopheles oswaldoi* a potential malaria vector in acre, Brazil. Transactions of the Royal Society of Tropical Medicine and Hygiene. 1996;**90**(3):233

[63] Marrelli MT, Branquinho MS, Hoffmann EH, Taipe-Lagos CB, Natal D, Kloetzel JK. Correlation between positive serology for *plasmodium vivax*like/*plasmodium simiovale* malaria parasites in the human and anopheline populations in the state of acre, Brazil. Transactions of the Royal Society of Tropical Medicine and Hygiene. 1998;**92**(2):149-151

[64] Malaria Threats Map–Parasite Drug Resistance, 2018. World Health Organization, Geneva. Available at: http://apps.who.int/malaria/maps/ threats/

[65] Woon SA, Manning L, Moore BR. Antimalarials for children with *plasmodium vivax* infection: Current status, challenges, and research priorities. Parasitology International. 2021;**13**:102512

[66] Rieckmann KH, Davis DR, Hutton DC. *Plasmodium vivax*  resistance to chloroquine? Lancet. 1989;**2**(8673):1183-1184

[67] Collignon P. Chloroquine resistance in *Plasmodium vivax*. The Journal of Infectious Diseases. 1991;**164**(1):222-223

[68] Whitby M, Wood G, Veenendaal JR, Rieckmann K. Chloroquine-resistant *Plasmodium vivax*. Lancet. 1989;**2**(8676):1395

[69] Schuurkamp GJ, Spicer PE, Kereu RK, Bulungol PK, Rieckmann KH. Chloroquine-resistant *Plasmodium vivax* in Papua New Guinea. Transactions of the Royal Society of Tropical Medicine and Hygiene. 1992;**86**(2):121-122

[70] Murphy GS, Basri H, Purnomo AEM, Bangs MJ, Mount DL, Gorden J, et al. Vivax malaria resistant to treatment and prophylaxis with chloroquine. Lancet. 1993;**341**(8837):96-100

[71] Garg M, Nagnur S, Potkar CN, Kshirsagar NA. General practitioners and treatment of malaria-need for continuing medical education. Journal of the Association of Physicians of India. 1995;**43**(8):584-585

[72] de Santana Filho FS, Arcanjo AR, Chehuan YM, Costa MR, Martinez-Espinosa FE, Vieira JL, et al. Chloroquine-resistant *Plasmodium vivax,* Brazilian Amazon. Emerging Infectious Diseases. 2007;**13**(7):1125-1126

[73] Marques J, Moles E, Urbán P, Prohens R, Busquets MA, Sevrin C, et al. Application of heparin as a dual agent with antimalarial and liposome targeting activities toward plasmodiuminfected red blood cells. Nanomedicine. 2014;**10**(8):1719-1728

[74] Pratt-Riccio LR, Baptista BO, Torres VR, Bianco-Junior C, Perce-Da-Silva DS, Riccio EKP, et al. Chloroquine and mefloquine resistance profiles are not related to the circumsporozoite protein (CSP) VK210 subtypes in field isolates of *Plasmodium vivax* from Manaus, Brazilian Amazon. Memórias do Instituto Oswaldo Cruz. 2019;**114**:e190054

[75] Kain KC, Brown AE, Lanar DE, Ballou WR, Webster HK. Response of *Plasmodium vivax* variants to chloroquine as determined by microscopy and quantitative polymerase chain reaction. American Journal of Tropical Medicine and Hygiene. 1993;**49**(4):478-484

[76] Andrade BB, Reis-Filho A, Souza-Neto SM, Clarêncio J, Camargo LMA, Barral A, et al. Severe *Circumsporozoite Protein from* Plasmodium vivax *and Its Relationship to Human Malaria DOI: http://dx.doi.org/10.5772/intechopen.102529*

*Plasmodium vivax* malaria exhibits marked inflammatory imbalance. Malaria Journal. 2010;**9**:13-20

[77] Medina TS, Costa SPT, Oliveira MD, Ventura AM, Souza JM, Gomes TF, et al. Increased interleukin10 and interferon-g levels in *plasmodium vivax* malaria suggest a reciprocal regulation which is not altered by IL-10 gene promoter polymorphism. Malar J. Bio Med Central Ltd. 2011;**10**:264

[78] Gimenez AM, Salman AM, Marques RF, López-Camacho C, Harrison K, Kim YC, et al. A universal vaccine candidate against plasmodium vivax malaria confers protective immunity against the three PvCSP alleles. Scientific Reports. 2021;**11**(1):17928

[79] de Camargo TM, de Freitas EO, Gimenez AM, Lima LC, de Almeida CK, Françoso KS, et al. Primeboost vaccination with recombinant protein and adenovirus-vector expressing *Plasmodium vivax* circumsporozoite protein (CSP) partially protects mice against Pb/Pv sporozoite challenge. Scientific Reports. 2018;**8**(1):1118

[80] Lima LC, Marques RF, Gimenez AM, Françoso KS, Aliprandini E, Camargo TM, et al. A multistage formulation based on full-length CSP and AMA-1 Ectodomain of *plasmodium vivax* induces high antibody Titers and T-cells and partially protects mice challenged with a transgenic *Plasmodium berghei* parasite. Microorganisms. 2020;**8**(6):916

[81] Yadava A, Waters NC. Rationale for further development of a vaccine based on the Circumsporozoite protein of *plasmodium vivax*. PLoS Neglected Tropical Diseases. 2017;**11**(1):e0005164 [82] Naz S, Ahmad S, Abbasi SW, Ismail S, Waseem S, Tahir Ul Qamar M, et al. Identification of immunodominant epitopes in allelic variants VK210 and VK247 of *plasmodium vivax* Circumsporozoite immunogen. Infection, Genetics and Evolution. 2021;**96**:105120

[83] Bennett JW et al. Phase 1/2a trial of *plasmodium vivax* malaria vaccine candidate VMP001/AS01B in malarianaive adults: Safety, immunogenicity, and efficacy. PLoS Neglected Tropical Diseases. 2016;**10**:e0004423
